Global Rare Disease Diagnostics Market is Projected to Hit USD 88,969.27 Million by 2032, With a CAGR of 9.2% From 2024 to 2032- Report by Polaris Market Research (PMR)
May 23, 2024 09:30 ET
|
Polaris Market Research & Consulting LLP
New York, May 23, 2024 (GLOBE NEWSWIRE) -- Market Overview: The global Rare Disease Diagnostics Market size is projected to grow from USD 40,227.42 million in 2023 to USD 88,969.27 million by 2032,...
Fc and Glycoengineered Antibodies Research 2024: Market Experiences Over 30% Growth in Collaborations in Past Two Years, Fueled by Strategic Partnerships - Long-term Forecasts to 2035
May 22, 2024 04:47 ET
|
Research and Markets
Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The "Fc and Glycoengineered Antibodies Market: Industry Trends and Global Forecasts, till 2035: Distribution by Type of Engineering, Type of Therapy,...
Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients
May 16, 2024 17:29 ET
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients
Mathew Hall, Sarcoidosis Warrior, Takes on Iron Man 70.3 Chattanooga to Raise Awareness and Support for Sarcoidosis
May 15, 2024 10:24 ET
|
Foundation for Sarcoidosis Research
Sarcoidosis warrior takes on Iron Man competition
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 07, 2024 08:30 ET
|
Inozyme Pharma Inc.
Inozyme reported financial results for the first quarter ended March 31, 2024 and provided business highlights.
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
May 01, 2024 08:00 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Kamari Pharma Appoints Dr. John Doux to its Board of Directors
April 30, 2024 09:00 ET
|
Kamari Pharma
NESS ZIONA, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- Kamari Pharma, a privately-held clinical stage biotechnology company developing first and best-in-class treatments for rare and severe genetic...
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
April 30, 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434 in a primate model of Parkinson’s...
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
April 22, 2024 08:00 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Kamari Pharma Announces Abstracts Accepted for Presentation at the 81st Annual Meeting of the Society for Investigative Dermatology
April 16, 2024 16:05 ET
|
Kamari Pharma
Late breaking poster presentation includes Phase 1b clinical trial results demonstrating the safety and preliminary efficacy of KM-001, a topical TRPV3 inhibitor, for the treatment of palmoplantar...